Your browser is no longer supported. Please, upgrade your browser.
Settings
HRTX [NASD]
Heron Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.39 Insider Own0.20% Shs Outstand101.91M Perf Week-4.55%
Market Cap991.48M Forward P/E- EPS next Y-1.97 Insider Trans-0.50% Shs Float101.77M Perf Month-28.41%
Income-228.30M PEG- EPS next Q-0.43 Inst Own- Short Float30.25% Perf Quarter-22.51%
Sales86.30M P/S11.49 EPS this Y0.00% Inst Trans3.92% Short Ratio19.58 Perf Half Y-38.93%
Book/sh1.17 P/B7.71 EPS next Y33.60% ROA-64.30% Target Price31.50 Perf Year-49.41%
Cash/sh1.85 P/C4.89 EPS next 5Y47.50% ROE-128.30% 52W Range8.42 - 22.40 Perf YTD-57.38%
Dividend- P/FCF- EPS past 5Y3.20% ROI-93.70% 52W High-59.73% Beta1.36
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin48.50% 52W Low7.17% ATR0.62
Employees223 Current Ratio4.40 Sales Q/Q16.00% Oper. Margin- RSI (14)36.65 Volatility7.62% 6.01%
OptionableYes Debt/Eq1.25 EPS Q/Q19.80% Profit Margin- Rel Volume2.34 Prev Close8.96
ShortableYes LT Debt/Eq1.25 EarningsNov 03 AMC Payout- Avg Volume1.57M Price9.02
Recom1.80 SMA20-12.66% SMA50-15.05% SMA200-33.59% Volume3,683,272 Change0.67%
May-27-20Initiated Guggenheim Buy $24
Feb-20-20Reiterated Needham Buy $50 → $48
Jan-16-19Reiterated Needham Buy $66 → $64
Apr-05-18Initiated Evercore ISI Outperform $56
Mar-19-18Reiterated Mizuho Buy $28 → $35
Mar-01-18Reiterated Needham Buy $28 → $30
Jan-03-18Initiated Leerink Partners Outperform $22
Sep-27-17Initiated Northland Capital Outperform $40
Feb-27-17Initiated Needham Buy $28
Oct-26-16Initiated Aegis Capital Buy
Sep-06-16Resumed Lake Street Buy $45
May-03-16Initiated Cantor Fitzgerald Buy
Dec-10-15Initiated Lake Street Buy $45
Sep-23-15Reiterated Leerink Partners Outperform $38 → $57
Sep-02-15Initiated BofA/Merrill Buy $46
Aug-03-15Reiterated Brean Capital Buy $40 → $45
Jun-30-15Reiterated JMP Securities Mkt Outperform $25 → $33
Jun-19-15Reiterated Leerink Partners Outperform $26 → $38
Aug-07-14Initiated Noble Financial Buy $18
Dec-06-21 01:42PM  
Nov-18-21 07:30AM  
Nov-11-21 04:05PM  
Nov-03-21 06:05PM  
04:01PM  
Oct-28-21 08:30AM  
Oct-11-21 10:00AM  
Oct-04-21 08:30AM  
Sep-21-21 04:05PM  
Sep-13-21 07:33PM  
Aug-15-21 03:35AM  
Aug-09-21 09:15AM  
08:00AM  
Jul-31-21 05:44AM  
Jul-28-21 04:05PM  
03:03PM  
Jul-21-21 04:05PM  
Jul-06-21 08:30AM  
Jul-01-21 08:30AM  
Jun-02-21 01:00PM  
May-25-21 04:05PM  
09:00AM  
May-13-21 10:22AM  
08:00AM  
May-10-21 03:33PM  
09:45AM  
08:30AM  
Apr-28-21 12:33PM  
Apr-22-21 03:47AM  
Apr-07-21 08:38AM  
Mar-26-21 02:34PM  
Feb-24-21 08:30AM  
Feb-21-21 03:24AM  
Feb-17-21 04:05PM  
Jan-21-21 08:30AM  
Jan-11-21 08:30AM  
Dec-29-20 08:57AM  
Dec-23-20 01:46AM  
Dec-19-20 01:06PM  
Nov-13-20 08:30AM  
Nov-11-20 04:05PM  
Nov-08-20 08:06AM  
Nov-05-20 08:30AM  
Nov-03-20 12:30PM  
Oct-23-20 02:05PM  
Oct-14-20 08:10AM  
Oct-06-20 05:05PM  
Sep-29-20 11:42AM  
Sep-28-20 08:30AM  
Sep-16-20 08:30AM  
Sep-11-20 04:05PM  
Sep-09-20 10:19AM  
Sep-08-20 08:30AM  
Aug-29-20 10:23AM  
Aug-12-20 01:00AM  
Aug-05-20 06:35PM  
Aug-04-20 11:26AM  
Jul-27-20 12:31PM  
Jul-24-20 10:29AM  
Jul-16-20 08:30AM  
Jul-02-20 10:38PM  
Jul-01-20 02:26PM  
Jun-30-20 11:15AM  
Jun-29-20 08:47AM  
08:45AM  
Jun-26-20 08:28AM  
Jun-23-20 07:51PM  
Jun-21-20 02:53PM  
Jun-16-20 10:00AM  
Jun-04-20 09:00AM  
May-20-20 10:04AM  
May-18-20 09:00AM  
May-09-20 08:00AM  
May-08-20 10:04AM  
May-06-20 10:35AM  
09:00AM  
May-05-20 07:31AM  
Apr-19-20 07:02AM  
Apr-09-20 04:05PM  
Apr-07-20 03:33PM  
Apr-05-20 09:57AM  
Mar-02-20 09:05AM  
07:30AM  
Feb-27-20 01:19PM  
08:42AM  
Feb-26-20 04:42PM  
Feb-21-20 12:30PM  
Feb-20-20 07:06AM  
Feb-19-20 06:16PM  
Feb-18-20 04:05PM  
Jan-27-20 11:01AM  
Jan-22-20 08:53AM  
Jan-13-20 08:30AM  
Dec-21-19 08:27AM  
Dec-16-19 04:05PM  
Dec-12-19 01:44PM  
Dec-10-19 05:18AM  
Dec-06-19 08:00AM  
Dec-03-19 07:30AM  
Nov-26-19 04:05PM  
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Christian WaageDirectorSep 21Sale12.313003,6923,500Sep 23 04:30 PM
Johnson Craig ADirectorSep 21Sale12.302503,0743,090Sep 23 04:29 PM
Christian WaageDirectorJun 21Sale15.203004,5593,800Jun 22 05:06 PM
Johnson Craig ADirectorJun 21Sale15.202503,8013,340Jun 22 05:05 PM
MANHARD KIMBERLYEVP, Drug DevelopmentMay 03Sale17.661,52927,0091,634May 04 06:03 PM
Christian WaageDirectorApr 15Sale17.513005,2544,100Apr 16 08:59 PM
Johnson Craig ADirectorApr 06Sale17.222504,3053,590Apr 07 05:04 PM
Szekeres David LeslieEVP, Chief Operating OfficerJan 14Sale18.0982714,9600Jan 15 04:30 PM
Szekeres David LeslieEVP, Chief Operating OfficerJan 08Sale19.663,57170,2190Jan 08 06:07 PM
MANHARD KIMBERLYEVP, Drug DevelopmentDec 22Option Exercise13.0010,000130,00010,000Dec 23 04:23 PM
MANHARD KIMBERLYEVP, Drug DevelopmentDec 22Sale20.0010,000200,0000Dec 23 04:23 PM